Scholarlink

Background <p>Chronic kidney disease-mineral and bone disorder (CKD-MBD) has been a prominent consequence of end-stage renal disease (ESRD), increasing cardiovascular risk and skeletal fragility. Emerging research shows that genetic and epigenetic variables play an important role in determining the development and progression of CKD-MBD. This study aimed to evaluate the potential role of calcium-sensing receptor (CaSR) rs1801725 polymorphism and the circulating microRNAs (miRNA-21-5p, miRNA-124-3p) as diagnostic biomarkers for CKD-MBD. This case-control study involved 100 Egyptian participants: 50 hemodialysis patients with CKD-MBD and 50 age- and sex-matched healthy controls. The CaSR rs1801725 polymorphism was genotyped using TaqMan<sup>®</sup> allelic discrimination assays. Through the use of real-time quantitative reverse transcription PCR (qRT-PCR), the expression levels of serum miRNA-21-5p and miRNA-124-3p were measured.</p> Results <p>The GT and TT genotypes of CaSR rs1801725 were more frequent in CKD-MBD patients but didn’t reach statistical significance. The TT genotype was linked to higher parathyroid hormone (PTH) and bone specific alkaline phosphatase (b-ALP) levels and lower calcium. Both miRNA-21-5p and miRNA-124-3p were notably downregulated in CKD-MBD, with miRNA-21-5p inversely correlating with PTH. Receiver operating characteristic (ROC) analysis suggests both miRNAs, especially miRNA-21-5p, could serve as diagnostic biomarkers.</p> Conclusions <p>This study highlights the potential of serum miRNA-21-5p and miRNA-124-3p expression levels, as promising biomarkers for CKD-MBD but CaSR rs1801725 polymorphism not reach statistical significance as an independent diagnostic marker.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Evaluation of CaSR rs1801725 and circulating miRNA-21-5p and miRNA-124-3p expression in chronic kidney disease-mineral and bone disorder patients

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月17日

查看全文
  • Enas Ahmed Osman,
  • Samia Hassan El-shishtawy,
  • Farida M. Khanany

摘要

Background

Chronic kidney disease-mineral and bone disorder (CKD-MBD) has been a prominent consequence of end-stage renal disease (ESRD), increasing cardiovascular risk and skeletal fragility. Emerging research shows that genetic and epigenetic variables play an important role in determining the development and progression of CKD-MBD. This study aimed to evaluate the potential role of calcium-sensing receptor (CaSR) rs1801725 polymorphism and the circulating microRNAs (miRNA-21-5p, miRNA-124-3p) as diagnostic biomarkers for CKD-MBD. This case-control study involved 100 Egyptian participants: 50 hemodialysis patients with CKD-MBD and 50 age- and sex-matched healthy controls. The CaSR rs1801725 polymorphism was genotyped using TaqMan® allelic discrimination assays. Through the use of real-time quantitative reverse transcription PCR (qRT-PCR), the expression levels of serum miRNA-21-5p and miRNA-124-3p were measured.

Results

The GT and TT genotypes of CaSR rs1801725 were more frequent in CKD-MBD patients but didn’t reach statistical significance. The TT genotype was linked to higher parathyroid hormone (PTH) and bone specific alkaline phosphatase (b-ALP) levels and lower calcium. Both miRNA-21-5p and miRNA-124-3p were notably downregulated in CKD-MBD, with miRNA-21-5p inversely correlating with PTH. Receiver operating characteristic (ROC) analysis suggests both miRNAs, especially miRNA-21-5p, could serve as diagnostic biomarkers.

Conclusions

This study highlights the potential of serum miRNA-21-5p and miRNA-124-3p expression levels, as promising biomarkers for CKD-MBD but CaSR rs1801725 polymorphism not reach statistical significance as an independent diagnostic marker.